依托泊苷和邻脂素的临床药理学
抽象
依托泊苷和替尼泊苷是半合成derivatives of podophyllotoxin and are increasingly used in cancer medicine. Teniposide is more highly protein-bound than etoposide, and its uptake and binding to cells is also greater. Etoposide and teniposide are phase-specific cytotoxic drugs acting in the late S and early G2 phases of the cell cycle. They appear to act by causing breaks in DNA via an interaction with DNA topoisomerase II or by the formation of free radicals. Teniposide is more potent as regards the production of DNA damage and cytotoxicity. Most studies show a biexponential decay following intravenous administration of etoposide and teniposide. The terminal elimination half-life of etoposide is less than that of teniposide, and the plasma and renal clearances of etoposide are greater. The peak plasma concentrations of drug and the area under the concentration versus time curve are linearly related to the intravenous dose of both drugs. Considerable interpatient variability of pharmacokinetic parameters exists following intravenous etoposide and teniposide. Various metabolites of etoposide and teniposide have been identified but their detection and quantitation are disputed. Approximately 30 to 70% of a dose of etoposide is accounted for by excretion, whereas the figure appears to be only 5 to 20% for teniposide. The bioavailability of oral etoposide is about 50% but its absorption is not linear with increasing dose within the range in clinical use. There is considerable inter- and intrapatient variability in the pharmacokinetics of oral etoposide. There is no evidence of accumulation of etoposide and teniposide after multiple consecutive doses by the intravenous or oral routes. The exact roles of the liver and kidney in metabolism and excretion of etoposide and teniposide are uncertain. Etoposide has been shown to be a highly schedule-dependent drug in clinical studies. This together with the phase-specific action of etoposide and teniposide and their increasingly widespread use in cancer medicine make the clinical pharmacology of these drugs of great clinical importance.
类似的文章
-
依托泊苷的临床药理学。癌症。1991年1月1日; 67(1)(1):319-29。DOI:10.1002 / 1097-0142(19910101)67:1+ <319 :: AID-CNCR2820671319> 3.0.co; 2-D。 癌症。1991年。 PMID:1984835. 评论。
-
胆囊毒素衍生物的临床药理学及安排依赖性。Semin Oncol。1992年APR; 19(2个8):20-7。 Semin Oncol。1992. PMID:1411635 评论。
-
Current development of podophyllotoxins.癌症化学其他药狼。1982; 7(2-3):93-8。DOI:10.1007 / BF00254528。 癌症化学其他药狼。1982年。 PMID:7044596 评论。
-
依托钠and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.Pharm Weekbl SCI。1988年6月17日; 10(3):101-16。DOI:10.1007 / BF01959294。 Pharm Weekbl SCI。1988年。 PMID:3047665 评论。
-
DNA破裂在人肺癌细胞和天然敏感或抗胸苷和邻脂素的核。癌症res。1986年8月; 46(8):3809-16。 癌症res。1986年。 PMID:3015377
引用d by41.文章
-
Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.医学(巴尔的摩)。2020年10月2; 99(40):E22637。DOI:10.1097 / MD.0000000000022637。 医学(巴尔的摩)。2020。 PMID:33019486. 免费PMC文章。
-
DNA拓扑异构酶作为抗癌药物的分子靶标。J Enzyme Inhib Med Chem. 2020 Dec;35(1):1781-1799. doi: 10.1080/14756366.2020.1821676. J Enzyme Inhib Med Chem. 2020. PMID:32975138. 免费PMC文章。
-
Cancer in the time of COVID-19: expert opinion on how to adapt current practice.EUR Respir J. 2020年5月14日; 55(5):2000959。DOI:10.1183 / 13993003.00959-2020。打印2020年5月。 EUR RESPIR J. 2020。 PMID:32299866 免费PMC文章。
-
利用天然产物总合成中的铁和α-酮戊基依赖性二恶英酶的生物催化潜力。NAT PROD REP。2020 8月1日; 37(8):1065-1079。DOI:10.1039 / C9np00075e。EPUB 2020 2月14日。 NAT产品代表2020。 PMID:32055818
-
( - ) - 管道毒素和相关芳基甲素蛋白的不对称化学酶合成。Angew Chem Int ED ENGL。2019年8月19日; 58(34):11657-11660。DOI:10.1002 / ANIE.201904102。EPUB 2019年7月17日。 Angew Chem Int ED ENGL。2019年。 PMID:31241812 免费PMC文章。
References
Publication types
网格术语
物质
Linkout - 更多资源
全文来源
其他文献来源